Clinical investigation
Postmenopausal use of estrogen and occlusion of coronary arteries

https://doi.org/10.1016/0002-8703(88)90063-4Get rights and content

Abstract

The degree of coronary artery occlusion was compared between users and nonusers of postmenopausal estrogen among 933 female patients undergoing angiography between the ages 50 and 75 years in the Milwaukee Cardiovascular Data Registry. Users (n = 154) had less occlusion than nonusers (n = 779), and a significant increase in occlusion scores with age was evident for nonusers (p < 0.001) but not for users (p = 0.50). The age-adjusted odds ratios for use of postmenopausal estrogen among women with moderate and severe levels of occlusion of the coronary arteries were 0.59 (95% confidence interval, 0.48 to 0.73) and 0.37 (95% confidence interval, 0.29 to 0.46), respectively, which indicated a statistically significant, apparent protective effect of postmenopausal estrogen on coronary occlusion. This effect was independent of the type of menopause or other risk factors but not independent of high-density lipoprotein-cholesterol levels. Higher high-density lipoprotein-cholesterol levels among users may indicate a biologic mechanism by which postmenopausal estrogen use lowers the risk of coronary occlusion.

References (43)

  • J.A. Cauley et al.

    Menopausal estrogen use, high density lipoprotein cholesterol subfractions and liver function

    Atherosclerosis

    (1983)
  • N.E. Borglin et al.

    Oral treatment of menopausal symptoms with natural estrogens: experiences with a new series of estrogens and oestrogen-gestagen combinations

    Acta Obstet Gynecol Scand

    (1975)
  • C. Bain et al.

    Use of postmenopausal hormones and risk of myocardial infarction

    Circulation

    (1981)
  • T. Bush et al.

    Estrogen use and all-cause mortality: preliminary results from the Lipid Research Clinics Program follow-up study

    JAMA

    (1983)
  • D.L. Kennedy et al.

    Noncontraceptive estrogens and progestins: use patterns over time

    Obstet Gynecol

    (1985)
  • T.L. Bush et al.

    Noncontraceptive estrogen use and cardiovascular disease

    Epidemiol Rev

    (1985)
  • P.W.F. Wilson et al.

    Postmenopausal estrogen use, cigarette smoking, and cardiovascular morbidity in women over 50

    N Engl J Med

    (1985)
  • M.J. Stampfer et al.

    A prospective study of postmenopausal estrogen therapy and coronary heart disease

    N Engl J Med

    (1985)
  • D.B. Petitti et al.

    Postmenopausal estrogen use and heart disease [Letter]

    N Engl J Med

    (1986)
  • M.C. Pike et al.

    Postmenopausal estrogen use and heart disease [Letter]

    N Engl J Med

    (1986)
  • A.M. Van Hemert

    Postmenopausal estrogen use and heart disease [Letter]

    N Engl J Med

    (1986)
  • P. Beck

    Postmenopausal estrogen use and heart disease [Letter]

    N Engl J Med

    (1986)
  • W. Thompson

    Postmenopausal estrogen use and heart disease [Letter]

    N Engl J Med

    (1986)
  • P.R.J. Burch

    Postmenopausal estrogen use and heart disease [Letter]

    N Engl J Med

    (1986)
  • H.G. Langford

    Postmenopausal estrogen use and heart disease [Letter]

    N Engl J Med

    (1986)
  • T.L. Bush

    Postmenopausal estrogen use and heart disease [Letter]

    N Engl J Med

    (1986)
  • P.W.F. Wilson et al.

    Postmenopausal estrogen use and heart disease [Letter]

    N Engl J Med

    (1986)
  • M.J. Stampfer et al.

    Postmenopausal estrogen use and heart disease [Letter]

    N Engl J Med

    (1986)
  • J.C. Bailar

    Postmenopausal estrogen use and heart disease [Letter]

    N Engl J Med

    (1986)
  • T.L. Bush et al.

    Cardiovascular mortality and noncontraceptive use of estrogen in women: results from the Lipid Research Clinics Program Follow-up Study

    Circulation

    (1987)
  • P. Wahl et al.

    Effect of estrogen/progestin potency on lipid/lipoprotein cholesterol

    N Engl J Med

    (1983)
  • Cited by (310)

    • Gaps, limitations and new insights on endogenous estrogen and follicle stimulating hormone as related to risk of cardiovascular disease in women traversing the menopause: A narrative review

      2017, Maturitas
      Citation Excerpt :

      This hypothesis has been supported by several evidence including: the lag of coronary heart disease (CHD) incidence in women behind men by 10 years [15], and the uncommon presence of CVD before menopause, but more common among young women with premature menopause or bilateral oophorectomy [16]. A decline/loss of ovarian hormones after menopause is associated with worse CVD risk factors as reported in many epidemiological studies [17–24]. As reviewed elsewhere in more detail [25], two consistent notions can be gleaned from these studies: (1) women lacking endogenous estradiol have a higher CVD risk than women having normal ovarian function, and (2) postmenopausal women on hormone therapy (HT) have lower incidence and prevalence of CVD.

    • Soy protein concentrate lowers serum high-density lipoprotein cholesterol concentrations compared with casein in ovariectomized rats fed a low-fat, cholesterol-free diet

      2007, Nutrition Research
      Citation Excerpt :

      Although the mechanisms responsible for these observations are not fully understood, these studies suggest that estrogen plays a significant role in the reduction in established risk factors for CHD [10,11], including favorable changes in HDL-C and LDL-C concentrations [12]. However, only 25% to 50% of the protective effects of estrogen are contributed by changes in lipoprotein levels [13]. Moreover, in animal models, estrogen has been shown to attenuate the development of atherosclerosis without changes in LDL concentration [14].

    View all citing articles on Scopus

    Supported in part by National Institutes of Health Grants R01-HL29011 and R01-HL28692 and by the Veterans Administration.

    View full text